PellePharm, Inc.
http://www.pellepharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PellePharm, Inc.
BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.
Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis
Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.
Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
BridgeBio’s $299m Gives It Two More Years Of Runway To Launch New Companies
The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- BridgeBio Pharma